Sequential intravesical mitomycin-C and gemcitabine therapy for BCG-unresponsive high-risk non-muscle-invasive bladder cancer: protocol for a prospective, open-label, single-arm, multicentre phase II (IMGeS) study.
- DOI
- 10.1136/bmjopen-2026-117239
- Published
- 2026 Oct 29
- Container
- BMJ open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjopen-2026-117239,
title = {Sequential intravesical mitomycin-C and gemcitabine therapy for BCG-unresponsive high-risk non-muscle-invasive bladder cancer: protocol for a prospective, open-label, single-arm, multicentre phase II (IMGeS) study.},
author = {Lee HW and Park YH and Kim KH and Jung EH and Song G and Lee HH and Lee DE and Kang SH and Jeong BC and Ham WS and Jung SI and Oh JJ and Seo HK},
year = {2026},
journal = {BMJ open},
doi = {10.1136/bmjopen-2026-117239},
url = {https://doi.org/10.1136/bmjopen-2026-117239}
}RIS
TY - JOUR TI - Sequential intravesical mitomycin-C and gemcitabine therapy for BCG-unresponsive high-risk non-muscle-invasive bladder cancer: protocol for a prospective, open-label, single-arm, multicentre phase II (IMGeS) study. AU - Lee HW AU - Park YH AU - Kim KH AU - Jung EH AU - Song G AU - Lee HH AU - Lee DE AU - Kang SH AU - Jeong BC AU - Ham WS AU - Jung SI AU - Oh JJ AU - Seo HK PY - 2026 JO - BMJ open DO - 10.1136/bmjopen-2026-117239 UR - https://doi.org/10.1136/bmjopen-2026-117239 ER -
APA
HW, L., YH, P., KH, K., EH, J., G, S., HH, L., DE, L., SH, K., BC, J., WS, H., SI, J., JJ, O., & HK, S. (2026). Sequential intravesical mitomycin-C and gemcitabine therapy for BCG-unresponsive high-risk non-muscle-invasive bladder cancer: protocol for a prospective, open-label, single-arm, multicentre phase II (IMGeS) study.. BMJ open. https://doi.org/10.1136/bmjopen-2026-117239
Source records
- pubmed · retrieved 2026-11-10T11:59:10.947Z